GLP-1 drugs like Ozempic might help clear Alzheimer’s disease plaques, new review suggests

A recent review published in Molecular and Cellular Neuroscience suggests that a popular class of diabetes and weight-loss medications might help reduce the biological markers associated with Alzheimer’s disease. By analyzing dozens of laboratory and animal studies, researchers found that GLP-1 receptor agonists consistently lower the brain proteins responsible for the progression of this dementia. The findings provide evidence for a promising avenue in future prevention efforts, though data in human patients remains limited.

Alzheimer’s disease is a progressive neurological disorder and the most common cause of dementia globally. It is biologically defined by two main microscopic features in the brain: amyloid-beta plaques and neurofibrillary tangles. Amyloid-beta is a protein fragment that can clump together outside nerve cells, forming sticky plaques that trigger inflammation and disrupt brain function.

Inside the nerve cells, another protein called tau provides structural support. In Alzheimer’s disease, tau undergoes a chemical change called hyperphosphorylation, causing it to become defective and twist into tangles. These tangles block the transport of nutrients and lead to the eventual death of the brain cell. Finding ways to clear or prevent these dual protein buildups is a primary goal for medical researchers.

Medical professionals note a strong biological connection between type 2 diabetes and Alzheimer’s disease. Patients with diabetes face a much higher risk of developing dementia later in life. In the brain, insulin resistance leads to the malfunction of specific cellular pathways, causing an increase in the enzymes that create amyloid-beta and tangle-forming tau proteins. This overlap leads scientists to suspect that medications regulating blood sugar might also protect the brain.

Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs like semaglutide and liraglutide, widely used to treat diabetes and obesity. They work by mimicking a natural hormone that prompts the body to produce insulin. Because the receptors for this hormone also exist in the brain’s memory centers, the authors of the current review wanted to evaluate whether these drugs directly impact the protein buildups that characterize Alzheimer’s disease.

Free daily newsletter

The research team conducted a systematic review of scientific literature published since 2015. They identified 30 preclinical studies involving animal or cell models, alongside two clinical studies involving human patients. The researchers categorized the results based on the specific drug tested, detailing the experimental methods and the subsequent changes in amyloid-beta and tau proteins.

Liraglutide was the most thoroughly evaluated medication, featured in roughly two-thirds of the preclinical studies. Researchers tested the drug in laboratory experiments using human brain cells and in animal models such as mice, rats, and non-human primates. These models were genetically or chemically altered to mimic the protein accumulations of Alzheimer’s disease.

In these studies, liraglutide consistently lowered both target proteins. Out of fifteen animal and cell studies measuring amyloid-beta, thirteen reported a reduction. All twelve studies measuring tau reported a decrease. The researchers noted that liraglutide appeared to work by suppressing an enzyme called BACE1, which is responsible for producing amyloid-beta, and by restoring insulin signaling pathways that prevent tau from tangling.

Dulaglutide was examined in only two preclinical studies. Scientists tested the drug by injecting it into mouse models of Alzheimer’s disease over several weeks. Both studies found that dulaglutide successfully lowered amyloid-beta accumulation and tau tangles. In these animal tests, the drug also tended to improve learning and memory impairment compared to untreated mice.

The review also evaluated exenatide, which was tested in eight preclinical studies involving diabetic and Alzheimer’s mouse models. The evidence for this drug was more mixed than for liraglutide. Six out of eight studies showed a decrease in amyloid-beta, while the remaining studies found no effect. All four studies that measured tau found a reduction, though one laboratory cell study noted that the drug only decreased tau tangles when insulin was also present in the cell culture.

Semaglutide, one of the most widely known drugs in this class, was featured in four animal studies. Scientists injected the medication into genetically modified mice over periods ranging from four to eight weeks. Three of these studies documented a reduction in amyloid-beta or tau. One study found no overall effect on amyloid-beta in mice, except for a localized reduction in the memory centers of female mice.

A single study examining a related drug, tirzepatide, found no reduction in plaques. That study even noted an increase in plaque area in the cerebral cortex among male mice.

Moving to human evidence, the review analyzed two small clinical trials. The first trial involved 38 patients with Alzheimer’s disease who received daily liraglutide injections or a placebo for 26 weeks. The results were not statistically significant regarding amyloid-beta reduction or cognitive improvement. The drug did, however, prevent the decline of brain glucose consumption, which is an indicator of sustained brain cell function.

The second clinical trial observed 21 patients with mild cognitive impairment who took exenatide or a placebo for 18 months. The researchers found no change in amyloid-beta or tau levels within the patients’ spinal fluid. They did notice a decrease of amyloid-beta in plasma extracellular vesicles, which are tiny fluid-filled sacs in the blood that can reflect brain changes.

Readers might assume that because these drugs clear brain plaques in mice, they will automatically reverse Alzheimer’s disease in humans. Animal models are designed to mimic specific, isolated features of the disease, such as rapid protein buildup or early genetic mutations. They do not replicate the widespread brain cell death and complex aging processes seen in actual human patients.

Scientists are still debating whether these medications actually enter the brain in large quantities. The drugs might reduce brain proteins indirectly by lowering systemic inflammation or improving overall cardiovascular health, rather than crossing the blood-brain barrier to interact directly with nerve cells. Improvements in cardiovascular health reduce the risk of micro-strokes and blood vessel damage, which are strong contributors to dementia.

The current clinical data suggests that GLP-1 drugs do not reverse cognitive decline once Alzheimer’s disease is fully established. Because structural changes in the brain begin years before memory loss becomes apparent, these medications might only be effective as preventive treatments rather than cures for late-stage dementia.

Future research will need to focus on large-scale human trials involving early-stage interventions. By tracking patients who take these medications over longer periods before severe cognitive symptoms arise, scientists can better determine if regulating metabolic health can truly prevent the onset of Alzheimer’s disease.

The study, “The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review,” was authored by Eve Corcoran, Michael Kettlety, Urwa Mogul, Jennifer Ndiforngwah Azah, and Simon C. Cork.